BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 383,100 shares, a growth of 174.0% from the September 15th total of 139,800 shares. Approximately 7.0% of the company’s shares are sold short. Based on an average daily trading volume, of 176,400 shares, the short-interest ratio is currently 2.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioVie stock. CVI Holdings LLC acquired a new stake in BioVie Inc. (NASDAQ:BIVI) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 599,897 shares of the company’s stock, valued at approximately $317,000. CVI Holdings LLC owned 1.50% of BioVie at the end of the most recent reporting period. 4.59% of the stock is currently owned by institutional investors.

BioVie Price Performance

Shares of NASDAQ:BIVI opened at $1.17 on Friday. The company has a market capitalization of $71.56 million, a price-to-earnings ratio of -1.24 and a beta of 0.67. The business’s 50-day moving average is $2.29 and its 200-day moving average is $1.10. BioVie has a 1 year low of $1.04 and a 1 year high of $58.20.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings data on Monday, September 30th. The company reported ($6.60) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, ThinkEquity started coverage on BioVie in a research report on Monday, July 1st. They issued a “buy” rating and a $3.00 price target on the stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.